siRNA-mediated ablation of ERα (32) or treating ER+ breast cancer cells with tamoxifen (38) (an ERα modulator) or fulvestrant (33, 38) – (a pure ERα antagonist that also leads to ERα degradation) blocks the E2-dependent upregulation of MDM2. Here, MDM2 is linked to breast carcinoma.